Founder’s Corner

Investing In
Innovvtive Thervpies

Our Portfolio

A2 Biotherapeutics, Inc.

A2 Biotherapeutics, Inc.

Creating the future of precision cell therapies
A2 Biotherapeutics, Inc.
Abcuro, Inc.

Abcuro, Inc.

Abcuro, Inc. is a clinical stage biotechnology company developing first-in-class immunotherapies for autoimmune diseases and cancer through precise modulation of T and NK cells that express KLRG1 (killer cell lectin like receptor G1).
Abcuro, Inc.
  • IPO
Abivax SA

Abivax SA

Abivax (ABVX) is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax SA
  • IPO
Acelyrin, Inc

Acelyrin, Inc

Acelyrin (SLRN) is a late-stage clinical biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising product candidates.
Acelyrin, Inc
Alamar Biosciences, Inc.

Alamar Biosciences, Inc.

Alamar Biosciences is a commercial proteomics company whose NULISA platform offer unrivalled precision, sensitivity and simplicity.
Alamar Biosciences, Inc.

Alentar

Reversing goblet cell hyperplasia for the benefit ​of patients with cystic fibrosis (CF) & other pulmonary conditions
  • IPO
Allakos, Inc.

Allakos, Inc.

Allakos, Inc. (ALLK) is a clinical-stage company developing antibodies that target receptor molecules present on the surface of immune effector cells involved in allergy, inflammation, tissue damage and proliferative disorders.
Allakos, Inc.
Alpha-9 Oncology, Inc.

Alpha-9 Oncology, Inc.

Alpha9 is developing potential best-in-class targeted radiopharmaceuticals for the treatment of cancer.
Alpha-9 Oncology, Inc.

Alpheus

Sonodynamic therapy for brain cancer
  • IPO
Alumis, Inc.

Alumis, Inc.

Alumis is transforming the lives of patients living with immune-mediated diseases using a precision approach to develop oral therapies.
Alumis, Inc.
  • IPO
Arcellx, Inc.

Arcellx, Inc.

Arcellx, Inc. (ACLX) is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer.
Arcellx, Inc.

Cold Start Therapeutics

Autobahn Labs, LLC

Autobahn Labs, LLC

Autobahn Labs accelerates the translation of novel science to realize the potential of academic research.
Autobahn Labs, LLC

Autobahn Therapeutics

Bionic Sight, Inc.

Bionic Sight, Inc.

Bionic Sight’s technology focuses on restoring sight to patients with advanced stage blindness due to retinal degenerative diseases.
Bionic Sight, Inc.
  • IPO
Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc (BOLT) is a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems.
Bolt Biotherapeutics, Inc.
  • IPO
CARGO Therapeutics

CARGO Therapeutics

CARGO (CARA), launched by Samsara in partnership with CAR T pioneers, is advancing a clinically validated CD22 CAR T for lymphoma.
CARGO Therapeutics
  • Acquired, IPO*
Chinook Therapeutics

Chinook Therapeutics

Chinook Therapeutics, Inc. (KDNY) is a biotechnology company developing precision medicines for kidney diseases. Chinook was acquired by Novartis in 2023.
Chinook Therapeutics
Codex Health, Inc.

Codex Health, Inc.

Codex Health develops clinical intelligence solutions for healthcare providers to bring the power of data-driven decision making into healthcare workflows.
Codex Health, Inc.
  • IPO
Contineum Therapeutics

Contineum Therapeutics

Continuem Therapeutics (CTNM) is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair.
Contineum Therapeutics
  • Acquired, IPO
Decibel Therapeutics

Decibel Therapeutics

Decibel Therapeutics, Inc. (DBTX) is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decible was acquired by Regeneron in 2023.
Decibel Therapeutics
Candid Therapeutics

Candid Therapeutics

Candid is pioneering a new frontier in autoimmune therapy with T-cell engager antibodies. By precisely redirecting T-cells to selectively eliminate autoreactive B-cells, Candid aims to achieve transformative efficacy safely.
Candid Therapeutics
Delfi Diagnostics, Inc.

Delfi Diagnostics, Inc.

Delfi utilizes novel machine learning algorithms to analyze fragments of cell-free DNA, resulting in the accurate detection of cancer from a single blood sample. Their product FirstLook, for early detection of lung cancer launched in 2023.
Delfi Diagnostics, Inc.
DewPoint Therapeutics, Inc.

DewPoint Therapeutics, Inc.

Dewpoint Therapeutics is developing a drug platform that targets biomolecular condensates, to pave the way for new approaches to treating the toughest diseases.
DewPoint Therapeutics, Inc.
  • Acquired
DICE Therapeutics

DICE Therapeutics

DICE Therapeutics (DICE) is a clinical-stage biopharmaceutical company combining innovative chemistry with well-validated biology to make medicines more accessible for people living with chronic autoimmune and inflammatory diseases.
DICE Therapeutics
ElevateBio, LLC

ElevateBio, LLC

Elevatebio is creating and operating a portfolio of cell and gene therapy companies to develop, manufacture and commercialize life-transforming medicines.
ElevateBio, LLC
Enara Bio, Ltd.

Enara Bio, Ltd.

Enara is developing therapies targeting Dark Antigens, a novel and differentiated class of cancer-specific targets from the genomic dark matter.
Enara Bio, Ltd.
Enlaza Therapeutics, Inc.

Enlaza Therapeutics, Inc.

Enlaza is developing first-in-class covalent protein therapeutics to transform the treatment of cancer and other serious diseases.
Enlaza Therapeutics, Inc.

Epibiologics

Exo Therapeutics, Inc.

Exo Therapeutics, Inc.

Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets.
Exo Therapeutics, Inc.

Excellergy Therapeutics

Developing best-in-class protein therapeutics for rapidly relieving or preventing allergic-mediated diseases.
  • Acquired
Eyebiotech Limited

Eyebiotech Limited

EyeBio is a clinical-stage ophthalmology biotech company delivering a clinical stage next-generation pipeline for back-of-the-eye diseases. EyeBio was acquired by Merck in 2024.
Eyebiotech Limited
  • Acquired
Fluent Biosciences, Inc.

Fluent Biosciences, Inc.

Fluent is a commercial stage life-sciences tools company, with a propietary technology enabling powerful single cell analysis in every laboratory without the use of complex instrumentation. Fluent was acquried by Illumina in 2024.
Fluent Biosciences, Inc.
  • Acquired, IPO
Forma Therapeutics

Forma Therapeutics

Forma Therapeutics (FMTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Forma was acquired by Novo Nordisk in 2022.
Forma Therapeutics

Genalyte, Inc.

Genalyte delivers rapid, actionable results to physicians through decentralized laboratory testing, backed by remote Telehealth oversight and monitoring.

Gossamer

Gossamer Bio is focused on the development of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
  • IPO
Hillevax, Inc.

Hillevax, Inc.

HilleVax (HLVX) is a biopharmaceutical company focused on the development and commercialization of novel vaccines.
Hillevax, Inc.
IntegerBio, Inc.

IntegerBio, Inc.

IntegerBio is a new immunovirology company harnessing the power of science, at the intersection of immunology and virology, to design broad therapeutics with durable response across multiple viruses.
IntegerBio, Inc.
  • Acquired
Intercept Pharmaceuticals

Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc. (ICPT) focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. Intercept was acquired by Alfasigma in 2023.
Intercept Pharmaceuticals

Inventiva

Developing lanifiranor for MASH
  • IPO
IO Biotech, Inc.

IO Biotech, Inc.

IO Biotech (IOBT) is a clinical-stage biopharmaceutical company pioneering the discovery and development of novel and highly differentiated immune-oncology therapeutics based on its proprietary technology platform, T-win®, which enables the activation of T cells that specifically target the immuno-suppressive tumor microenvironment.
IO Biotech, Inc.
  • Acquired
Iveric Bio

Iveric Bio

IVERIC bio (ISEE) is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. Iveric was acquired by Astellas in 2023.
Iveric Bio
  • IPO

Janux Therapeutics, Inc.

  • IPO*
Kalaris Therapeutics, Inc. (F/K/A Theia)

Kalaris Therapeutics, Inc. (F/K/A Theia)

Kalaris is developing a best-in-class approach for neovascular retinal diseases.
Kalaris Therapeutics, Inc. (F/K/A Theia)
LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc.

LENZ Therapeutics (LENZ) is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision.
LENZ Therapeutics, Inc.
Link Cell Therapies Inc.

Link Cell Therapies Inc.

Link Cell Therapies is developing a breakthrough logic-gate technology to enable the development of CAR-T for patients with solid tumors.
Link Cell Therapies Inc.

Maro Bio

Platform company developing new agents for hematologic diseases
  • IPO
Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. (MLYS) is a clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension.
Mineralys Therapeutics, Inc.
  • Acquired
Miro Bio

Miro Bio

MiroBio is developing novel, best-in-class therapeutics that bring significant benefits to patients suffering from a range of auto-immune diseases. MiroBio was acquired by Gilead in 2022.
Miro Bio
Neurogastrx, Inc.

Neurogastrx, Inc.

Neurogastrx is developing trasnformative therapies to advance the treatment of GI disorders for which meaningful therapeutic innovation is required to satisfy unmet patient need and disease burden.
Neurogastrx, Inc.
  • IPO*
Neurogene Inc

Neurogene Inc

Neurogene (NGNE) is accelerating development of new genetic medicines to people with devastating neurological diseases.
Neurogene Inc

Nikang Therapeutics, Inc.

Nikang Therapeutics is a clinical-stage biotech company dedicated to developing innovative small molecule drugs against high-value targets for oncology.
  • IPO
Nkarta, Inc.

Nkarta, Inc.

Nkarta Therapeutics (NKTX) is developing allogeneic or off-the-shelf cell therapies for cancer and auto-immune disease based on Natural Killer (NK) cells.
Nkarta, Inc.
Nura, Inc.

Nura, Inc.

Nura Bio is aspiring to develop disease modifying therapeutics to improve the lives of patient and families struggling with neurodegenerative disorders.
Nura, Inc.
  • IPO*
OnKure, Inc.

OnKure, Inc.

OnKure is engaged in the discovery and development of targeted small molecule therapies for the treatment of cancer that include selective mutant specific inhibitors of PI3K for the treatment of breast cancer.
OnKure, Inc.
Orso Bio

Orso Bio

OrsoBio is developing novel approaches to treat patients with severe metabolic disorders, including obesity, diabetes, severe dyslipidemias, NASH, and more.
Orso Bio

Ottimo

Ottimo Pharma is developing first-in-class, one-of-a-kind PD-1/VEGFR2 dual pathway antibodies to extend the lives of people living with cancer.

Pathalys Pharma

Pathalys Pharma is committed to improving the lives of patients through the development of enhanced therapeutics that improve the management of chronic kidney disease (CKD).
  • IPO*
Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc.

Palvella Therapeutics is a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for serious genetic diseases with no approved treatments.
Palvella Therapeutics, Inc.
  • IPO
Prime Medicine, Inc.

Prime Medicine, Inc.

Prime Medicine (PRME) is delivering a new class of curative genetic therapies to address a wide spectrum of diseases by deploying Prime Editing technology.
Prime Medicine, Inc.
Primmune Therapeutics Inc

Primmune Therapeutics Inc

Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases.
Primmune Therapeutics Inc

PsiThera

PsiThera is using high-level molecular dynamics (MD) simulations combined with machine learning (ML) in “computation-first” small molecule drug discovery.

Rani

Rani Therapeutics has developed a disruptive technology for the oral delivery of biologics.
  • Acquired, IPO
Rayze Bio

Rayze Bio

RayzeBio (RYZB) is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. RayzeBio was acquired by Bristol Myers Squibb in 2023.
Rayze Bio
Respira

Respira

Respira is developing next-generation cardiopulmonary disease-targeted inhalation products.
Respira
Scholar Rock Holding Corp, Inc.

Scholar Rock Holding Corp, Inc.

Scholar Rock (SRRK) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases by targeting the Transforming Growth Factor Beta pathway.
Scholar Rock Holding Corp, Inc.

Shenandoah

Next-generation chemical inducers of proximity to hijack cancer drivers as cancer cures
  • IPO
Septerna, Inc

Septerna, Inc

Pioneering a New Era of GPCR Drug Discovery.
Septerna, Inc

Sidera

  • IPO
SpyGlass Pharma, Inc

SpyGlass Pharma, Inc

Spyglass Pharma is developing a controlled release drug delivery platform for ophthalmic applications starting with glaucoma.
SpyGlass Pharma, Inc
  • IPO
Sutro BioPharma, Inc.

Sutro BioPharma, Inc.

Sutro Biopharma (STRO) is a clinical-stage company developing next generation antibody drug conjugates (ADCs) for the treatment of cancer using their proprietary cell-free protein manufacturing technology.
Sutro BioPharma, Inc.
Synthekine, Inc.

Synthekine, Inc.

Synthekine is a clinical-stage company focused on discovery and developing best-in-lass cytokine therapeutics.
Synthekine, Inc.
Tentarix Biotherapeutics, LP

Tentarix Biotherapeutics, LP

Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology.
Tentarix Biotherapeutics, LP
  • IPO
Upstream Bio, Inc.

Upstream Bio, Inc.

Upstream Bio develops therapies that treat inflammatory and allergic diseases with their lead asset, an anti-TSLPR monoclonal antibody in phase II study.
Upstream Bio, Inc.

VTV Therapeutics Inc

vTv Therapeutics is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates.

IPO* denotes company that went public via reverse merger.

Shopping Basket